Well, I've been following this company for about 3 years now and have done plenty of due dilligence. Without getting into details, that scenario just doesn't add up and makes no sense.
For one thing Abbott has been working on incorporating the recaf technology into their architect system for almost 2 years, which tells me that they have invested much more $ than the announced $200,000 upfront payment into developing the technology. It's more like a few million. They are getting very close to commercialization. They have already change the format of the test into a working prototype that is close to being as effective as the original, which used the undesirable radio-active material.
News 
Market Data 
Discover 
